title: Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
abstract: BACKGROUND
  Experimental studies have suggested that vasopressin plays a detrimental role in autosomal dominant polycystic kidney disease (ADPKD). It is, however, unknown whether endogenous vasopressin concentration is associated with kidney function decline in subjects with ADPKD.
  
  
  METHODS
  We measured plasma copeptin (a marker of vasopressin) in 79 ADPKD subjects with renal function assessed during short-term follow-up by inulin clearance measured glomerular filtration rate (mGFR) and during long-term follow-up by Modification of Diet in Renal Disease (MDRD) equation estimated GFR (eGFR).
  
  
  RESULTS
  In these subjects (43% male, age 36.8 ± 10.1 years, GFR 96.8 ± 18.2 mL/min/1.73 m(2)), median copeptin concentration at baseline was 2.71 [interquartile ranges (IQR) 1.63-5.46] pmol/L. Baseline copeptin concentration was inversely associated both with change in mGFR during follow-up for 3.3 (3.1-3.5) years, (R = -0.300, P = 0.01), as well as with change in eGFR during follow-up for 11.2 (4.5-14.3) years, (R = -0.302, P < 0.01). These associations were independent of age, gender and baseline GFR. Nine subjects started renal replacement therapy during follow-up of which eight had at baseline a copeptin concentration above the median in this population.
  
  
  CONCLUSIONS
  In ADPKD subjects, a higher copeptin concentration is associated with kidney function decline during follow-up, suggesting that copeptin may be a new marker to predict kidney outcome in ADPKD.
authors.affiliation: Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Wendy E
authors.initials: WE
authors.lastname: Boertien
authors.forename: Esther
authors.initials: E
authors.lastname: Meijer
authors.forename: Debbie
authors.initials: D
authors.lastname: Zittema
authors.forename: Marjan A
authors.initials: MA
authors.lastname: van Dijk
authors.forename: Ton J
authors.initials: TJ
authors.lastname: Rabelink
authors.forename: Martijn H
authors.initials: MH
authors.lastname: Breuning
authors.forename: Joachim
authors.initials: J
authors.lastname: Struck
authors.forename: Stephan J L
authors.initials: SJ
authors.lastname: Bakker
authors.forename: Dorien J M
authors.initials: DJ
authors.lastname: Peters
authors.forename: Paul E
authors.initials: PE
authors.lastname: de Jong
authors.forename: Ron T
authors.initials: RT
authors.lastname: Gansevoort
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006020:Glycopeptides / Q000097:blood*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D016891:Polycystic Kidney, Autosomal Dominant / Q000097:blood / Q000503:physiopathology*; D014667:Vasopressins / Q000097:blood*
chemical_list: D015415:Biomarkers; D006020:Glycopeptides; C048197:copeptins; D014667:Vasopressins